Skip to main content
. 2022 Feb 4;12(2):e050510. doi: 10.1136/bmjopen-2021-050510

Table 1.

Baseline characteristics of low-dose aspirin and paracetamol users*

Characteristics Before propensity score matching After propensity score matching
Low-dose aspirin
(n=60 869)
Paracetamol
(n=367 290)
Standardised
difference†
Low-dose aspirin
(n=49 679)
Paracetamol
(n=49 679)
Standardised
difference†
Age, mean (SD), years 69.1 (12.5) 57.6 (12.8) 0.912 68.0 (12.5) 69.1 (12.7) 0.09
Female 29 010 (47.7) 211 841 (57.7) 0.202 24 031 (48.4) 23 991 (48.3) 0.002
Aspirin dose
 ≤100 mg 52 125 (85.6) – – 42 756 (86.1) – –
 101 mg – 200 mg 7396 (12.2) – – 5909 (11.9) – –
 200 mg – 300 mg 1348 (2.2) – – 1014 (2.0) – –
Medical conditions
 Hypertension 12 679 (20.8) 18 469 (5.0) 0.485 8651 (17.4) 8626 (17.4) 0.001
 Congestive heart failure 3676 (6.0) 1568 (0.4) 0.321 1734 (3.5) 1289 (2.6) 0.05
 Arrhythmia and conduction disorders 8397 (13.8) 3563 (1.0) 0.506 3915 (7.9) 2900 (5.8) 0.08
 Arterial disease 601 (1.0) 578 (0.2) 0.110 378 (0.8) 321 (0.6) 0.01
 Valve disorders 436 (0.7) 579 (0.2) 0.085 266 (0.5) 254 (0.5) 0.003
 Cardiomyopathy 329 (0.5) 149 (0.0) 0.093 165 (0.3) 114 (0.2) 0.02
 Diabetes mellitus 9079 (14.9) 12 148 (3.3) 0.412 6079 (12.2) 5975 (12.0) 0.006
 Hyperlipidaemia 2130 (3.5) 2662 (0.7) 0.194 1400 (2.8) 1325 (2.7) 0.009
 Thyroid disorders 1189 (2.0) 4644 (1.3) 0.055 851 (1.7) 837 (1.7) 0.002
 Major bleeding 408 (0.7) 1269 (0.3) 0.046 316 (0.6) 343 (0.7) 0.007
 COPD 2868 (4.7) 6214 (1.7) 0.172 2062 (4.2) 2109 (4.2) 0.005
 Obesity 214 (0.4) 358 (0.1) 0.054 139 (0.3) 144 (0.3) 0.002
 CKD 1359 (2.2) 1343 (0.4) 0.165 801 (1.6) 737 (1.5) 0.01
 Chronic liver disease 544 (0.9) 1953 (0.5) 0.043 437 (0.9) 462 (0.9) 0.005
 GERD 150 (0.2) 410 (0.1) 0.032 105 (0.2) 115 (0.2) 0.004
 Irritable bowel syndrome 45 (0.1) 293 (0.1) 0.002 37 (0.1) 41 (0.1) 0.003
 Peptic ulcer 244 (0.4) 952 (0.3) 0.025 193 (0.4) 186 (0.4) 0.002
 Inflammatory bowel disease 11 (0.0) 106 (0.0) 0.007 10 (0.0) 8 (0.0) 0.003
 Alcoholism 1166 (1.9) 3005 (0.8) 0.095 826 (1.7) 836 (1.7) 0.002
 Schizophrenia 1125 (1.8) 5699 (1.6) 0.023 900 (1.8) 916 (1.8) 0.002
 Bipolar disorder 95 (0.2) 706 (0.2) 0.009 87 (0.2) 98 (0.2) 0.005
 Depression 1158 (1.9) 6291 (1.7) 0.014 943 (1.9) 942 (1.9) <0.001
Medications
 Diuretics 14 350 (23.6) 28 961 (7.9) 0.441 10 042 (20.2) 10 136 (20.4) 0.005
 ACE inhibitor or ARB 16 819 (27.6) 20 267 (5.5) 0.623 11 195 (22.5) 11 003 (22.1) 0.009
 Other antihypertensives 8785 (14.4) 18 471 (5.0) 0.321 6384 (12.9) 6676 (13.4) 0.02
 CCB 22 514 (37.0) 45 062 (12.3) 0.599 16 622 (33.5) 17 637 (35.5) 0.04
 Antiarrhythmic 1562 (2.6) 1335 (0.4) 0.184 760 (1.5) 537 (1.1) 0.04
 Beta-blockers 21 756 (35.7) 42 667 (11.6) 0.592 15 777 (31.8) 16 466 (33.1) 0.03
 Peripheral vasodilators 741 (1.2) 598 (0.2) 0.128 435 (0.9) 373 (0.8) 0.01
 Oral hypoglycaemic 14 789 (24.3) 25 443 (6.9) 0.493 10 799 (21.7) 11 260 (22.7) 0.02
 Insulin 3321 (5.5) 2686 (0.7) 0.275 1972 (4.0) 1790 (3.6) 0.02
 Lipid lowering drugs 10 680 (17.5) 10 362 (2.8) 0.502 7019 (14.1) 6835 (13.8) 0.01
 PPI or H2-blockers 21 143 (34.7) 39 028 (10.6) 0.601 14 323 (28.8) 13 898 (28.0) 0.02
 NSAID 8324 (13.7) 62 026 (16.9) 0.089 7137 (14.4) 7503 (15.1) 0.02
 Oral bisphosphonates 245 (0.4) 455 (0.1) 0.054 182 (0.4) 186 (0.4) 0.001
 Oral corticosteroids 7561 (12.4) 30 915 (8.4) 0.131 5913 (11.9) 6136 (12.4) 0.01
 Anticoagulants 2537 (4.2) 1359 (0.4) 0.257 1278 (2.6) 962 (1.9) 0.04
 Antiplatelet 1408 (2.3) 328 (0.1) 0.205 532 (1.1) 316 (0.6) 0.05
 Antipsychotics 2172 (3.6) 7718 (2.1) 0.088 1664 (3.3) 1708 (3.4) 0.005
 Antidepressants 2583 (4.2) 10 947 (3.0) 0.068 2063 (4.2) 2110 (4.2) 0.005

*Values are expressed as frequency (%) unless otherwise specified.

†Standardised difference indicates difference in mean or proportion of covariates in the low-dose aspirin group versus the paracetamol group divided by the pooled SD.

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GERD, gastro-oesophageal reflux disease; H2-blockers, histamine-2 receptor blockers; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitors.